Matt Davidson - 28 Oct 2026 Form 4 Insider Report for ADIAL PHARMACEUTICALS, INC. (ADIL)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
30 Oct 2026, 20:44:35 UTC
Prior SEC filing
16 Jun 2026
Next SEC filing
04 Nov 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Matthew Gene Davidson
Filing notes and source

Key filing fact

Matt Davidson filed Form 4 for ADIAL PHARMACEUTICALS, INC. (ADIL) on 30 Oct 2026.

Key facts

  • This page summarizes Matt Davidson's Form 4 filing for ADIAL PHARMACEUTICALS, INC. (ADIL).
  • 7 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 30 Oct 2026, 20:44.

Change

  • Previous filing in this sequence was filed on 16 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001741937 Primary reporting owner

Davidson Matt

Relationship
President and CEO, Director
Address
C/O AZORA THERAPEUTICS, INC., 16501 VENTURA BLVD., SUITE 400, ENCINO
Signature
/s/ Matthew Gene Davidson
Signature date
30 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ADIL transaction

Common Stock

Award

Transaction value
Shares
+232,417
Change %
+377%
Price
$0.000000*
Shares after
294,064
Date
28 Oct 2026
Ownership
Direct
Footnotes
F1, F2, F3
ADIL holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
3,427
Date
28 Oct 2026
Ownership
By Matt and Alli Davidson Trust
Footnotes
F13

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ADIL transaction Derivative

Series A Preferred Stock

Award

Transaction value
Shares
+1,822
Change %
Price
Shares after
1,822
Date
28 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
1,822,130
Exercise price
Footnotes
F2, F4, F5
ADIL transaction Derivative

Series A Preferred Stock

Award

Transaction value
Shares
+101
Change %
Price
Shares after
101
Date
28 Oct 2026
Ownership
By Matt and Alli Davidson Trust
Underlying class
Common Stock
Underlying amount
101,298
Exercise price
Footnotes
F2, F5, F6
ADIL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+232,417
Change %
Price
$0.000000*
Shares after
232,417
Date
28 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
232,417
Exercise price
$2.98
Footnotes
F7, F8
ADIL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+286,044
Change %
Price
Shares after
286,044
Date
28 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
286,044
Exercise price
$0.5400
Footnotes
F9, F10
ADIL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+31,914
Change %
Price
Shares after
31,914
Date
28 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
31,914
Exercise price
$1.57
Footnotes
F10, F11
ADIL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares
+333,830
Change %
Price
Shares after
333,830
Date
28 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
333,830
Exercise price
$0.6300
Footnotes
F12
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 13 footnotes

Footnote F1

On June 11, 2026, the Issuer acquired the private Delaware corporation which was then known as Azora Therapeutics, Inc. ("Old Azora") in accordance with the Agreement and Plan of Merger, dated June 11, 2026 ("Merger Agreement"), by and among the Issuer, Adial Merger Sub, Inc., a wholly owned subsidiary of the Issuer ("First Merger Sub"), Adial Second Merger Sub, LLC, a wholly owned subsidiary of the Issuer ("Second Merger Sub"), and Old Azora.

Footnote F2

Under the terms of the Merger Agreement, on June 11, 2026, First Merger Sub merged with and into Old Azora, with Old Azora surviving the first merger as a wholly owned subsidiary of the Issuer, and immediately following the first merger, Old Azora merged with and into Second Merger Sub, with Second Merger Sub surviving the second merger as a wholly owned subsidiary of the Issuer (such mergers, collectively the "Merger"). Upon the closing of the Merger, shares of outstanding common stock, Series A-1 Preferred Stock, Series A-2 Preferred Stock and Series A-3 Preferred Stock of Old Azora were converted into the right to receive shares of the Issuer's common stock ("Common Stock") and Series A Non-Voting Convertible Preferred Stock ("Series A Preferred Stock") in accordance with the Merger Agreement.

Footnote F3

As previously reported, represents an award of restricted stock units ("RSUs"). On June 11, 2026, the Issuer's board of directors approved the RSUs to be issued on June 12, 2026, contingent on stockholder approval of the issuance of Common Stock upon conversion of the Series A Preferred Stock (the "Preferred Stock Conversion Proposal"). Stockholders approved the Preferred Stock Conversion Proposal on October 28, 2026 (the "Conversion Proposal Approval Date"). In addition, the RSUs' vesting terms were amended October 28, 2026 to provide that the RSUs vest as to 25% of the shares on the first anniversary of the grant date (June 12, 2026), with the remaining shares vesting in a series of 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through the applicable vesting date.

Footnote F4

Received, along with 61,647 shares of Common Stock previously reported, in exchange for 5,902,500 shares of Old Azora common stock in connection with the Merger Agreement.

Footnote F5

Subject to certain conditions set forth in the Merger Agreement (including receiving stockholder approval of the Preferred Stock Conversion Proposal) and the Certificate of Designation of the Series A Preferred Stock (which contains certain beneficial ownership and other limits), each share of Series A Preferred Stock is convertible into 1,000 shares of Common Stock and has no expiration date. The Series A Preferred Stock will convert automatically into Common Stock within three business days following the Conversion Proposal Approval Date.

Footnote F6

Received, along with 3,427 shares of Common Stock previously reported, in exchange for 200,000 shares of Series A-1 Preferred Stock and 128,138 shares of Series A-2 Preferred Stock of Old Azora in connection with the Merger Agreement. The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust.

Footnote F7

The exercise price reported on this item corrects a scrivener's error on the Reporting Person's Form 4 filed on June 16, 2026, which inadvertently stated the exercise price for the option as $2.89. The correct amount is $2.98 as reported herein.

Footnote F8

As previously reported, on June 11, 2026, the Issuer's board of directors approved the option grant issued to the Reporting Person on June 12, 2026, contingent on stockholder approval of the Preferred Stock Conversion Proposal. The Issuer's stockholders approved the Preferred Stock Conversion Proposal on the Conversion Proposal Approval Date. In addition, the option's vesting terms were amended October 28, 2026 to provide that the option vests as to 25% of the shares on the first anniversary of the grant date (June 12, 2026), with the remaining shares vesting in a series of 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through the applicable vesting date.

Footnote F9

Received in exchange for a stock option to acquire 896,272 shares of Old Azora common stock with an exercise price of $0.17 per share, which grant was subject to stockholder approval of the Preferred Stock Conversion Proposal. The Issuer's stockholders approved the Preferred Stock Conversion Proposal on the Conversion Proposal Approval Date.

Footnote F10

Immediately exercisable.

Footnote F11

Received in exchange for a stock option to acquire 100,000 shares of Old Azora common stock with an exercise price of $0.50 per share pursuant to the Merger Agreement, which grant was subject to stockholder approval of the Preferred Stock Conversion Proposal. The Issuer's stockholders approved the Preferred Stock Conversion Proposal on the Conversion Proposal Approval Date.

Footnote F12

Received in exchange for a stock option to acquire 1,046,000 shares of Old Azora common stock with an exercise price of $0.20 per share pursuant to the Merger Agreement, which grant was subject to stockholder approval of the Preferred Stock Conversion Proposal. The Issuer's stockholders approved the Preferred Stock Conversion Proposal on the Conversion Proposal Approval Date. The option vests as to 25% of the shares on the first anniversary of the vesting commencement date (April 20, 2026), with the remaining shares vesting in a series of 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through the applicable vesting date.

Footnote F13

The Reporting Person serves as co-trustee of the Matt and Alli Davidson Trust.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .